Filters
Frequent consumption of spicy food appears to protect against the risk of gastrointestinal cancers, especially oesophageal cancer, and this association is pronounced among individuals who do not smoke and drink regularly, according to a study.
A recent study has found a higher risk of cancer incidence in patients with idiopathic pulmonary fibrosis (IPF) than in those without IPF. Thus, healthcare providers should be made aware of such risk when treating IPF patients.
Bayer reveals major transformation in its pharmaceutical business with the use of breakthrough innovations aimed at helping patients with difficult-to-treat conditions.
Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.
The addition of obinutuzumab or rituximab to chemotherapy* (O-CT or R-CT, respectively) similarly led to HRQoL** improvements in patients with previously untreated advanced follicular lymphoma (FL), according to the phase III GALLIUM study.
In the final analysis of the phase III ClarIDHy trial, ivosidenib was well-tolerated and had a favourable overall survival (OS) benefit despite a high crossover rate from placebo among individuals with previously treated advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (mIDH1 CCA).
In the treatment of small cell lung cancer, the combination of an immune checkpoint inhibitor plus chemotherapy boosts response and patient survival compared with chemotherapy alone, according to the results of a meta-analysis.
The addition of the human immunoglobulin G1 monoclonal antibody ramucirumab to paclitaxel led to a significant progression-free survival (PFS) benefit in a subgroup of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed standard first-line chemotherapy with platinum and fluoropyrimidine (with or without anthracycline), according to the findings of the RAINBOW-Asia study, a bridging study of the RAINBOW trial, presented at ASCO GI 2021.
Obesity, particularly central obesity, seems to correlate with a more aggressive breast cancer phenotype, a recent study has found. The impact of breast volume, on the other hand, is less clear.
Fewer women with visual impairment (VI) undergo mammography screening for breast cancer compared to their counterparts without VI, a study has shown.
